Advisor Group Holdings, Inc. Lineage Cell Therapeutics, Inc. Transaction History
Advisor Group Holdings, Inc.
- $42.2 Billion
- Q3 2024
A detailed history of Advisor Group Holdings, Inc. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 64,051 shares of LCTX stock, worth $32,025. This represents 0.0% of its overall portfolio holdings.
Number of Shares
64,051
Previous 47,139
35.88%
Holding current value
$32,025
Previous $47,000
23.4%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding LCTX
# of Institutions
121Shares Held
94.2MCall Options Held
63.8KPut Options Held
1K-
Broadwood Capital Inc New York, NY41.7MShares$20.8 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$4.78 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.6MShares$4.3 Million0.0% of portfolio
-
Defender Capital, Llc.5MShares$2.5 Million1.58% of portfolio
-
Logos Global Management LP San Francisco, CA5MShares$2.5 Million0.6% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $84.9M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...